Brokerages Set AstraZeneca PLC (LON:AZN) Target Price at £104.12

AstraZeneca PLC (LON:AZN) has been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is GBX 7,935.67 ($99.00).

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a £140 ($174.65) price objective on shares of AstraZeneca in a research note on Friday, November 22nd. Berenberg Bank reiterated a “buy” rating and set a GBX 140 ($1.75) price objective on shares of AstraZeneca in a report on Monday. Finally, Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th.

AstraZeneca Price Performance

Shares of AZN opened at £106.68 ($133.08) on Friday. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market capitalization of £165.35 billion, a price-to-earnings ratio of 3,386.67, a P/E/G ratio of 0.86 and a beta of 0.17. The business’s 50-day moving average is £105.13 and its 200-day moving average is £116.82. AstraZeneca has a fifty-two week low of GBX 9,461 ($118.03) and a fifty-two week high of £133.88 ($167.02).

Insider Activity at AstraZeneca

In related news, insider Pascal Soriot purchased 20,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The shares were bought at an average cost of £102.03 ($127.28) per share, for a total transaction of £2,040,600 ($2,545,658.68). Also, insider Tony Mok purchased 1,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average price of £126.80 ($158.18) per share, for a total transaction of £190,200 ($237,275.45). 0.04% of the stock is owned by corporate insiders.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.